Enzo Biochem(US:ENZ)2021-12-14 16:00Financial Performance - Revenues for the three months ended October 31, 2021, were $26,519 thousand, a decrease of 7.5% compared to $28,655 thousand for the same period in 2020[16] - Total operating costs and expenses for the same period were $28,351 thousand, slightly up from $28,158 thousand in 2020, resulting in an operating loss of $1,832 thousand[16] - The net loss for the three months ended October 31, 2021, was $2,319 thousand, compared to a net income of $299 thousand in the same period of 2020, reflecting a significant decline[16] - The company reported a basic net loss per common share of $0.05 for the three months ended October 31, 2021, compared to a basic net income per share of $0.01 in 2020[16] - For the three months ended October 31, 2021, the company reported a net loss of $2,319,000 compared to a net income of $299,000 for the same period in 2020[25] - The company reported a decrease in accounts receivable of $1,120,000 for the three months ended October 31, 2021, compared to a decrease of $2,865,000 in the same period of 2020[25] - The company reported capital expenditures of $1.033 million for the three months ended October 31, 2021[100] - Total operating costs and expenses increased to $28,351 thousand, up from $28,158 thousand in the prior year, resulting in an operating loss of $1,832 thousand compared to an operating income of $497 thousand in 2020[17] - Net loss for the period was $2,319 thousand, compared to a net income of $299 thousand in the same period last year, reflecting a significant decline in profitability[19] Cash and Liquidity - Cash and cash equivalents decreased to $6,356 thousand as of October 31, 2021, down from $13,524 thousand at July 31, 2021[13] - Total assets decreased to $108,139 thousand as of October 31, 2021, compared to $113,691 thousand at July 31, 2021[13] - The company reported inventories of $13,957 million as of October 31, 2021, an increase from $12,652 million as of July 31, 2021[61] - Total cash and cash equivalents and restricted cash at the end of the period was $7,106,000, down from $46,664,000 at the end of the same period last year[25] - Cash and cash equivalents at the end of the period were $6,356 thousand, down from $45,914 thousand at the end of October 31, 2020, indicating a decrease in liquidity[25] - Net cash used in operating activities was $6,043 thousand for the three months ended October 31, 2021, significantly higher than $1,208 thousand for the same period in 2020[25] Assets and Liabilities - Total liabilities decreased to $41,379 thousand as of October 31, 2021, from $45,105 thousand at July 31, 2021[13] - Stockholders' equity as of October 31, 2021, was $66,760 thousand, down from $68,586 thousand at July 31, 2021[13] - Current liabilities decreased to $23.106 million from $26.076 million, a reduction of about 11.3%[13] - The company reported an accumulated deficit of $272.696 million as of October 31, 2021, compared to $270.377 million at the end of July 2021, indicating an increase in the deficit[13] Revenue Breakdown - Clinical services revenue accounted for 74% of total revenues for both the three months ended October 31, 2021, and 2020[46] - Total clinical services net revenues for the three months ended October 31, 2021, were $19,741 million, a decrease from $21,223 million in the same period of 2020[55] - Revenue from third-party payers was $11,397 million, representing 58% of clinical services revenue, down from 64% in the prior year[55] - Products revenue for the three months ended October 31, 2021, was $6,778 million, compared to $7,432 million in the same period of 2020[57] - Medicare revenue was $2,880 million (14% of clinical services revenue) for the three months ended October 31, 2021, down from $3,257 million (15%) in 2020[55] - Patient self-pay revenue decreased to $1,945 million (10% of clinical services revenue) in the three months ended October 31, 2021, from $2,559 million (12%) in 2020[55] Expenses and Costs - Research and development expenses remained relatively stable at $744 thousand for the three months ended October 31, 2021, compared to $746 thousand in 2020[16] - Share-based compensation expense for the three months ended October 31, 2021, totaled $216 million, an increase from $167 million in the same period of 2020, reflecting a rise of about 29.3%[87] - The operating lease cost for the three months ended October 31, 2021, was $1,158 million, compared to $1,479 million for the same period in 2020, representing a decline of approximately 21.7%[74] - The company accrued PSU compensation expense of $66,000 for the three months ended October 31, 2021, while no expense was accrued in the same period of 2020[95] Legal and Regulatory Matters - The company is involved in ongoing litigation with Harbert Discovery Fund, alleging false and misleading representations in proxy materials[108] - The court denied Harbert's motion to dismiss the company's misrepresentation claims on September 28, 2021, allowing the company to pursue these claims[108] - Management believes that any potential liabilities from ongoing litigations will not have a material adverse effect on the company's financial position[109] Management and Governance - The company appointed Hamid Erfanian as CEO on November 8, 2021, who has over 28 years of experience in the healthcare sector[111] - The company granted equity awards to the new CEO, including 260,000 restricted stock units and options to purchase 700,000 shares, with an exercise price of $3.39[111] Market and Economic Conditions - The impact of the COVID-19 pandemic continues to affect the company's operations, with significant reductions in physician office visits and elective medical procedures[27] - Management emphasizes that the results for the three months ended October 31, 2021, are not necessarily indicative of future performance for the fiscal year ending July 31, 2022[26]